Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes in SCI
NCT03113994Phase 2Terminated
- Start
- Feb 2018
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of rosuvastatin in osteoporosis, metabolic syndrome. Started Feb 2018; status: terminated.
02
Drugs
rosuvastatin
03
Conditions
osteoporosismetabolic syndrome
Beyond the preview
Go deeper on NCT03113994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113994.